Research Article
Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide
Table 2
Treatment adherence and persistence results.
| | Variables | Total () | Subjects with ≥2 identifiable CVD risk factor(s) () |
| | Continuation status | | | | Continued, (%) | 119 (50.4%) | 80 (47.3%) | | Discontinued, (%) | 117 (49.6%) | 89 (52.7%) | | Treatment duration, mean days (SD) | 236.8 (124.9) | 230.5 (125.0) | | PDC, mean (SD) | 0.6 (0.3) | 0.63 (0.34) | | Adherence, (%) | | | | Yes () | 115 (48.7%) | 78 (46.2%) | | No () | 121 (51.3%) | 91 (53.8%) | | Switching | | | | Yes, (%) | 97 (41.1%) | 63 (37.3%) | | 1.5 mg to 0.75 mg in 1st switching | 7 (7.2%) | 4 (6.3%) | | 0.75 mg to 1.5 mg in 1st switching | 90 (92.8%) | 59 (93.7%) | | No, (%) | 139 (58.9%) | 106 (62.7%) | | Adverse events | | | | Nausea, (%) | 1 (0.4%) | 0 (0%) | | Vomiting | 0 (0.0%) | 0 (0.0%) | | Diarrhea | 0 (0.0%) | 0 (0.0%) | | Indigestion, (%) | 2 (0.8%) | 1 (0.6%) | | Abdominal pain, n (%) | 3 (1.3%) | 3 (1.8%) | | Lower abdominal pain, (%) | 1 (0.4%) | 1 (0.6%) | | Hyperglycemia, (%) | 2 (0.8%) | 2 (1.2%) | | Hypoglycemia, (%) | 1 (0.4%) | 0 (0%) | | Impaired fasting glucose, (%) | 1 (0.4%) | 1 (0.6%) | | Foot ulcer, (%) | 1 (0.4%) | 0 (0%) | | Gastroparesis, (%) | 1 (0.4%) | 1 (0.6%) | | Pancreatitis, (%) | 0 (0.0%) | 0 (0.0%) |
|
|
SD: standard deviation; PDC: proportion of days covered.
|
